A Phase 2/3 interventional study of Nintedanib and Pemetrexed in Mesothelioma, sponsored by Boehringer Ingelheim. Terminated at 123 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-18.
Sponsored by Boehringer Ingelheim · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Mesothelioma with a site in United States — 35 open to participants now, 50 under way, 1 of them phase 3. Mesothelioma · United States.
Among the 188 studies in Mesothelioma with a site in United States, this one is the 4th largest by enrollment of the 164 interventional ones that give a count, is one of 7 that started in 2013, is one of 2 in phase 2/3, and was the 51st registered.
305 studies on the registry are indexed under Mesothelioma; 61 are open to participants now.
Browse Mesothelioma studies →35 of the 188 studies in Mesothelioma with a site in United States are open now. Recruiting first, the newest first:
SHY Therapeutics · Sites in United States
Ages 18+
Orion Corporation, Orion Pharma · Sites in United States, Denmark, Finland and 4 more countries
Ages 18+
IDEAYA Biosciences · Sites in United States, Korea, Republic of
Ages 18+
University of Chicago · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Mesothelioma studies recruiting now, 33 (69%) set no upper age limit and 4 (8%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 104 · Phase 2 73 · Phase 3 6
First in 2000; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 545 is above the median of 48 across 250 interventional studies indexed under Mesothelioma.
Median enrollment 46 across the 164 interventional studies, 100 across the 23 observational. Of the 124 that completed or were terminated, 54 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
92 of 188 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 1 study filed under Mesothelioma — fewer than ten, so there is no comparison to draw.
15 of the studies in Mesothelioma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538376Brigham and Women's HospitalClinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU | 2026-11 |
| NCT05238883HiFiBiO TherapeuticsA Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
| NCT05647265Alliance for Clinical Trials in OncologyTesting the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma | 2026-12-15 |
| NCT04857372Novartis PharmaceuticalsA Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | 2027-01-07 |
| NCT05873686Nuvectis Pharma, Inc.A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 188 studies in Mesothelioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo controlled arm
Drug: Pemetrexed · Drug: Cisplatin · Drug: Placebo
Experimental arm
Drug: Nintedanib · Drug: Cisplatin · Drug: Pemetrexed
triple kinase inhibitor; 200mg starting dose
backbone chemo
backbone chemo
backbone chemo
backbone chemo
Nintedanib matching placebo
Progression-Free Survival (PFS)
This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day.
Time frame: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)
Overall Survival (OS)
Overall survival was defined as the duration of time from randomization to time of death. This is the key secondary endpoint of the trial.
Time frame: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)
Objective Response According to Modified RECIST- Investigator Assessment
Objective response (best overall tumour response of confirmed complete response \[CR\] or confirmed partial response \[PR\]). Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement. Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part.
Time frame: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months
Disease Control According to Modified RECIST- Investigator Assessment
Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST. Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part.
Time frame: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months
Patients were initially treated with combination therapy consisting of nintedanib or placebo plus standard chemotherapy (pemetrexed/cisplatin), for a maximum of 6 cycles of 21 days duration. After completion of combination therapy, patients who had not progressed continued with nintedanib or placebo monotherapy.
| Milestone | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III |
|---|---|---|---|---|
| Started | 43 | 44 | 229 | 229 |
| Treated patients | 41 | 44 | 228 | 227 |
| Completed | 1 | 4 | 82 | 83 |
| Not completed | 42 | 40 | 147 | 146 |
| Withdrew: Pd based on modified recist criteria | 31 | 32 | 95 | 92 |
| Withdrew: Withdrawal by subject | 2 | 5 | 10 | 13 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Not treated | 2 | 0 | 1 | 2 |
| Withdrew: Other than reasons specified | 1 | 0 | 10 | 6 |
| Withdrew: Adverse event (ae) | 6 | 3 | 22 | 23 |
| Withdrew: Worsening/ae underlying cancer disease | 0 | 0 | 8 | 8 |
This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day.
| Months | Placebo | Nintedanib |
|---|---|---|
| Phase II | 5.72 (5.19 to 8.18) | 9.36 (5.55 to 12.65) |
| Phase III | 6.97 (5.42 to 9.00) | 6.77 (5.36 to 9.07) |
Overall survival was defined as the duration of time from randomization to time of death. This is the key secondary endpoint of the trial.
| Months | Placebo | Nintedanib |
|---|---|---|
| Phase II | 14.46 (10.41 to NA) | 18.30 (10.91 to NA) |
| Phase III | 16.07 (9.66 to 19.29) | 14.36 (9.13 to 18.69) |
Objective response (best overall tumour response of confirmed complete response \[CR\] or confirmed partial response \[PR\]). Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement. Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part.
| Percentage of participants | Placebo | Nintedanib |
|---|---|---|
| Objective Response According to Modified RECIST- Investigator Assessment | 42.8 (36.3 to 49.5) | 45.0 (38.4 to 51.7) |
Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST. Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part.
| Percentage of participants | Placebo | Nintedanib |
|---|---|---|
| Disease Control According to Modified RECIST- Investigator Assessment | 92.6 (88.4 to 95.6) | 90.8 (86.3 to 94.2) |
Collected over SAE & Non SAE: From first dose until 28 days (Phase II) or 30 days (Phase III) after last dose, up to approximately (approx.) 30 months in Phase II and approx. 32 months in Phase III. All-cause mortality: From randomization until end of follow-up, up to approx. 30 months in Phase II and approx. 32 months in Phase III. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo_Phase II | 25/43 (58.1%) | 17/41 (41.5%) | 41/41 (100%) |
| Nintedanib_Phase II | 22/44 (50%) | 16/44 (36.4%) | 44/44 (100%) |
| Placebo_Phase III | 63/229 (27.5%) | 89/228 (39%) | 219/228 (96.1%) |
| Nintedanib_Phase III | 64/229 (27.9%) | 99/227 (43.6%) | 218/227 (96%) |
| Event | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III |
|---|---|---|---|---|
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/41 | 0/44 | 7/228 | 13/227 |
| NeutropeniaBlood and lymphatic system disorders | 1/41 | 3/44 | 7/228 | 6/227 |
| DiarrhoeaGastrointestinal disorders | 0/41 | 3/44 | 7/228 | 8/227 |
| PyrexiaGeneral disorders | 2/41 | 3/44 | 10/228 | 4/227 |
| Lower respiratory tract infectionInfections and infestations | 2/41 | 0/44 | 2/228 | 4/227 |
| DehydrationMetabolism and nutrition disorders | 2/41 | 2/44 | 8/228 | 4/227 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/41 | 1/44 | 2/228 | 0/227 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/41 | 2/44 | 6/228 | 5/227 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/41 | 0/44 | 6/228 | 4/227 |
| AnaemiaBlood and lymphatic system disorders | 1/41 | 2/44 | 8/228 | 1/227 |
| Event | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 34/41 | 37/44 | 134/228 | 156/227 |
| DiarrhoeaGastrointestinal disorders | 15/41 | 29/44 | 47/228 | 118/227 |
| VomitingGastrointestinal disorders | 20/41 | 24/44 | 66/228 | 96/227 |
| NeutropeniaBlood and lymphatic system disorders | 9/41 | 22/44 | 82/228 | 83/227 |
| ConstipationGastrointestinal disorders | 19/41 | 17/44 | 73/228 | 60/227 |
| AnaemiaBlood and lymphatic system disorders | 9/41 | 16/44 | 94/228 | 76/227 |
| FatigueGeneral disorders | 15/41 | 18/44 | 62/228 | 60/227 |
| Decreased appetiteMetabolism and nutrition disorders | 16/41 | 17/44 | 66/228 | 66/227 |
| Alanine aminotransferase increasedInvestigations | 1/41 | 17/44 | 10/228 | 35/227 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/41 | 15/44 | 33/228 | 29/227 |
Randomised Set: This patient set included all randomized patients.
| Age, Continuous(Years) | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III | Total |
|---|---|---|---|---|---|
| Mean | 65.9 ± 7.6 | 66.4 ± 8.6 | 64.3 ± 8.9 | 63.6 ± 9.5 | 64.3 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III | Total |
|---|---|---|---|---|---|
| Female | 8 | 10 | 60 | 64 | 142 |
| Male | 35 | 34 | 169 | 165 | 403 |
| Ethnicity (NIH/OMB)(Participants) | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | — | — | — | — | 0 |
| Not Hispanic or Latino | — | — | — | — | 0 |
| Unknown or Not Reported | — | — | — | — | 0 |
| Race (NIH/OMB)(Participants) | Placebo_Phase II | Nintedanib_Phase II | Placebo_Phase III | Nintedanib_Phase III | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 14 | 12 | 26 |
| Asian | 0 | 0 | 16 | 14 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 2 |
| White | 38 | 38 | 180 | 185 | 441 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 6 | 19 | 16 | 46 |
Showing the first 100 of 123 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Mar 2018, 53 months.
Results were first posted in Mar 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib